Neuronetics

NeuroStar® Advanced Therapy to Host Contact Sensing Challenge at Psych Congress

October 19, 2018

Leading TMS manufacturer has delivered more than two million treatments to depression patients across the country

MALVERN, Pa., October 25, 2018 —NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), will host a "Contact Sensing Challenge" demonstration at the 31st Annual U.S. Psychiatric & Mental Health Congress (Psych Congress) in Orlando, October 25-27, 2018. Psych Congress is the nation's leading independent mental health continuing education conference for advancing psychopharmacology, psychotherapy and wellness.

NeuroStar is the only TMS system on the market that provides contact sensing technology to deliver the right dose to the right location every time to treat depression and maximize a patient's chance of achieving remission. The Contact Sensing Challenge will allow attendees to witness how easy it can be to lose contact during treatment if the TMS system being used lacks the ability to monitor patient position. The smallest movement by the patient during treatment can result in a dramatic loss of the prescribed TMS dose. Even a one millimeter movement (equivalent to three grains of salt) of the head away from the coil can result in 40% less of the TMS prescribed dose. Continuous contact sensing solves this problem.

"As a trailblazer in the treatment of depression, NeuroStar is committed to the pursuit of cutting-edge TMS technology, and through collaboration with the clinical community we will continue to improve care for the millions of Americans suffering from depression," said Chris Thatcher, President and CEO of Neuronetics, Inc. "With NeuroStar, physicians are armed with the confidence of knowing their patients are being effectively treated during every session, providing them with the possible chance of long-term remission from depression."

During the Psych Congress, NeuroStar will also host "Meet the Expert" sessions in their booth #325 with Anita Riggs, Clinical Director of Healing House in Orlando, to share the latest TMS updates and their practice's experience and outcomes with the NeuroStar treatment.

With more than two million treatments delivered to date, NeuroStar Advanced Therapy was the first TMS device to receive FDA clearance in 2008 as a safe and effective option for adult patients with Major Depressive Disorder (MDD). NeuroStar has become a game changer in the treatment of depression and offers hope to the 5.5 million adults in the U.S. with depression who do not see relief from antidepressant medication.1,2,3 In fact, NeuroStar is backed with the most clinical studies for TMS in depression and has proven efficacy for patients with MDD.4,5,6

In honor of National Depression Awareness Month, NeuroStar Advanced Therapy will be executing a national television broadcast campaign alongside an awareness-building initiative to educate the public on

transcranial magnetic stimulation as an innovative depression treatment option, while sparking crucial conversations on breaking mental health stigma.

For more information about NeuroStar Advanced Therapy, visit www.NeuroStar.com.

About NeuroStar® Advanced Therapy

NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors for patients with MDD, and is widely available across the United States.

NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.

NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05)5. The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.

NeuroStar® is a registered trademark of Neuronetics, Inc. (NASDAQ:STIM). For more information and full safety and prescribing information, visit www.neurostar.com.

1 Kessler RC, et al. JAMA, (2003)

2 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018

3 Gaynes BN et al., Cleveland Clinic Journal of Medicine 2008;75(1):57-66

4 Carpenter LL, et al. Depress Anxiety, (2012)

5 George MS, et al. Arch Gen Psychiatry, (2010)

6 O'Reardon JP, et al. Biological Psychiatry, (2007)

Media Contact:

Meagan Dominick

Office: 610-455-2779

Mobile: 773-369-4255

mdominick@vaultcommunications.com